Inhibitor-resistant TEM β-lactamases: Phenotypic, genetic and biochemical characteristics

Journal of Antimicrobial Chemotherapy

Volumn 43, Issue 4, 1999, Pages 447-458

  Chaibi E B ^a   Sirot, D ^b   Paul, G ^c   Labia, R ^a  

^a UMR 175   (France)

^b UNIVERSITÉ CLERMONT AUVERGNE   (France)

^c Institut Cochin   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAMASE; CLAVULANIC ACID; SULBACTAM; TAZOBACTAM;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; BACTERIAL GENETICS; PHENOTYPE; REVIEW;

EID: 0343686104     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/43.4.447     Document Type: Review

References (77)

1. Martinez, J. L., Vicente, M. F., Delgado-Iribarren, A., Perez-Diaz, J. C. & Baquero, F. (1989). Small plasmids are involved in amoxycillin-clavulanate resistance in Escherichia coli. Antimicrobial Agents and Chemotherapy 33, 595.
2. Wu, P.-J., Shannon, K. & Phillips, I. (1994). Effect of hyperproduction of TEM-1 β-lactamase on in vitro susceptibility of Escherichia coli to β-lactam antibiotics. Antimicrobial Agents and Chemotherapy 38, 494-8.
3. Wu, P.-J., Shannon, K. & Phillips, I. (1995). Mechanisms of hyperproduction of TEM-1 β-lactamase by clinical isolates of Escherichia coli. Journal of Antimicrobial Chemotherapy 36, 927-39.
4. Reguera, J. A., Baquero, F., Pérez-Diaz, J. C. & Martinez, J. L. (1991). Factors determining resistance to β-lactam combined with β-lactamase inhibitors in Escherichia coli. Journal of Antimicrobial Chemotherapy 27, 569-75.
5. Bergström, S. & Normark, S. (1979). β-Lactam resistance in clinical isolates of Escherichia coli caused by elevated production of the ampC-mediated chromosomal β-lactamase. Antimicrobial Agents and Chemotherapy 16, 427-33.
6. Thomson, C. J. & Amyes, S. G. B. (1992). TRC-1: emergence of a clavulanic acid TEM β-lactamase in a clinical strain. FEMS Microbiology Letters 70, 113-18.
7. Vedel, G., Belaaouaj, A., Gilly, L., Labia, R., Philippon, A., Névot, P. et al. (1992). Clinical isolates of Escherichia coli producing TRI β-lactamases: novel TEM-enzymes conferring resistance to β-lactamase inhibitors. Journal of Antimicrobial Chemotherapy 30, 449-62.
8. Belaaouaj, A., Lapoumeroulie, C., Caniça, M. M., Vedel, G., Névot, P., Krishnamoorthy, R. et al. (1994). Nucleotide sequences of the genes coding for the TEM-like β-lactamases IRT-1 and IRT-2 (formerly called TRI-1 and TRI-2). FEMS Microbiology Letters 120, 75-80.
9. Zhou, X. Y., Bordon, F., Sirot, D., Kitzis, M.-D. & Gutmann, L. (1994). Emergence of clinical isolates Escherichia coli producing TEM-1 derivatives or an OXA-1 β-lactamase conferring resistance to β-lactamase-inhibitors. Antimicrobial Agents and Chemotherapy 38, 1085-9.
10. Brun, T., Péduzzi, J., Canica, M. M., Paul, G., Névot, P., Barthélémy, M. et al. (1994). Characterization and amino-acid sequence of IRT-4, a novel TEM-type enzyme with a decreased susceptibility to β-lactamase inhibitors. FEMS Microbiology Letters 120, 111-17.
11. Henquell, C., Chanal, C., Sirot, D., Labia, R. & Sirot, J. (1995). Molecular characterization of nine different types of mutants among 107 inhibitor-resistant TEM β-lactamases from clinical isolates of Escherichia coli. Antimicrobial Agents and Chemotherapy 39, 427-30.
12. Bret, L., Chanal, C., Sirot, D., Labia, R. & Sirot, J. (1996). Characterization of an inhibitor-resistant enzyme IRT-2 derived from TEM-2 β-lactamase produced by Proteus mirabilis strains. Journal of Antimicrobial Chemotherapy 38, 183-91.
13. TEM genes encoding β-lactamases resistant to clavulanic acid in clinical E. coli. Journal of Molecular Evolution 44, 57-65.
14. Bret, L., Chaibi, E. B., Chanal-Claris, C., Sirot, D., Labia, R. & Sirot, J. (1997). Inhibitor-resistant TEM (IRT) β-lactamases with different substitutions at position 244. Antimicrobial Agents and Chemotherapy 41, 2547-9.
15. Speldooren, V., Heym, B., Labia, R. & Nicolas-Chanoine, M.-H. (1998). Discriminatory detection of inhibitor-resistant β-lactamases in Escherichia coli by single-strand conformation polymorphism PCR. Antimicrobial Agents and Chemotherapy 42, 879-84.
16. Blazquez, J., Baquero, M. R., Canton, R., Alos, I. & Baquero, F. (1993). Characterization of a new TEM type β-lactamase resistant to clavulanate, sulbactam, and tazobactam in a clinical isolate of Escherichia coli. Antimicrobial Agents and Chemotherapy 37, 2059-63.
17. Stapleton, P., Wu, P.-J., King, A., Shannon, K., French, G. & Phillips, I. (1995). Incidence and mechanisms of resistance to the combination of amoxycillin and clavulanic acid in Escherichia coli. Antimicrobial Agents and Chemotherapy 39, 2478-83.
18. Lemozy, J., Sirot, D., Chanal, C., Huc, C., Labia, R., Dabernat, H. et al. (1995). First characterization of inhibitor-resistant TEM (IRT) β-lactamases in Klebsiella pneumoniae strains. Antimicrobial Agents and Chemotherapy 39, 2580-2.
19. Bermudes, H., Jude, F., Arpin, C., Quentin, C., Morand, A. & Labia, R. (1997). Characterization of an inhibitor-resistant TEM (IRT) β-lactamase in a novel strain of Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy 41, 222.
20. Hunter, J. E. B., Corkill, J. E., McLennan, A. G., Fletcher, J. N. & Hart, C. A. (1993). Plasmid encoded β-lactamases resistant to inhibition by clavulanic acid produced by calf faecal coliforms. Research in Veterinary Science 55, 367-70.
21. Nicolas-Chanoine, M. H. (1997). Inhibitor-resistant β-lactamases. Journal of Antimicrobial Chemotherapy 10, 1-3.
22. Bémer-Melchior, P., Gilly, L., Jugroot-Klotz, K., Brun, T., Névot, P. & Paul, G. (1995). Etude de la résistance à l'amoxicilline et à l'association amoxicilline-acide clavulanique dans 231 souches cliniques d'Escherichia coli isolées en 1992 à l'hôpital Cochin. Pathologie Biologie 43, 760-5.
23. Henquell, C., Sirot, D., Chanal, C., De Champs, C., Chatron, P., Lafeuille, B. et al. (1994). Frequency of inhibitor-resistant TEM β-lactamases in Escherichia coli isolates from urinary tract infections in France. Journal of Antimicrobial Chemotherapy 34, 707-14.
24. Romaszko, J.-P., Bret, L., Henquell, C., Sirot, D., Chanal, C. & Sirot, J. (1995). Detection of inhibitor-resistant TEM β-lactamases by disc diffusion method. Pathologie Biologie 43, 306-9.
25. Sirot, D., Chanal, C., Henquell, C., Labia, R., Sirot, J. & Cluzel, R. (1994). Clinical isolates of Escherichia coli producing multiple TEM mutants resistant to β-lactamase inhibitors. Journal of Antimicrobial Chemotherapy 33, 1117-26.
26. Acar, J., Chardon, H., Choutet, P., Courvalin, P., Dabernat, H., Drugeon, H. et al. (1996). Comité de l'antibiogramme de la Société Française de Microbiologie. Pathologie Biologie 44, 1-8.
27. Libert, J. M., Naudin, F., Mougeot, C. & Sirot, D. (1997). Détection en routine des bêta-lactamases TEM résistantes aux inhibiteurs (IRT) et des oxacillinases (OXA) chez Escherichia coli. Pathologie Biologie 45, 34-40.
28. Bret, L., Peyret, M., Romaszko, J.-P., Henquell, C., Sirot, D., Chanal, C. et al. (1995). Detection of inhibitor-resistant TEM β-lactamases (IRT) on ATB Plus system. In Abstracts of the Seventh European Congress of Clinical Microbiology and Infectious Diseases, Vienna. Abstract 167. Excepta Medica Medical Communications, Vienna, Austria.
29. Sutcliffe, J. G. (1978). Nucleotide sequence of the ampicillin resistance gene of Escherichia coli plasmid pBR322. Proceedings of the National Academy of Sciences of the USA 75, 3737-41.
30. Chen, S. T. & Clowes, R. C. (1987). Variations between the nucleotide sequences of Tn1, Tn2, and Tn3 and expression of β-lactamase in Pseudomonas aeruginosa and Escherichia coli. Journal of Bacteriology 169, 913-16.
31. Hawley, D. K. & McClure, W. R. (1983). Compilation and analysis of Escherichia coli promoter DNA sequences. Nucleic Acids Research 11, 2237-55.
32. Siu, L. K., Ho, P. L., Yuen, K. Y., Wong, S. S. Y. & Chau, P. Y. (1997). Transferable hyperproduction of TEM-1 β-lactamase in Shigella flexneri due to a point mutation in the Pribnow box. Antimicrobial Agents and Chemotherapy 41, 468-70.
33. Chaibi, E. B., Péduzzi, J., Farzaneh, S., Barthélémy, M., Sirot, D. & Labia, R. (1998). Clinical inhibitor-resistant mutants of the β-lactamase TEM-1 at amino-acid position 69. Kinetic analysis and molecular modelling. Biochimica et Biophysics Acta 1382, 38-46.
34. Bonomo, R. A., Rudin, S. A. & Shlaes, D. M. (1997). Tazobactam is a potent inactivator of selected inhibitor-resistant class A β-lactamases. FEMS Microbiology Letters 148, 59-62.
35. Bush, K., Macalintal, C., Rasmussen, B. A., Lee, V. J. & Yang, Y. (1993). Kinetic interactions of tazobactam with β-lactamases from all major structural classes. Antimicrobial Agents and Chemotherapy 37, 851-8.
36. Payne, D. J., Cramp, R., Winstanley, D. J. & Knowles, D. J. C. (1994). Comparative activities of clavulanic acid, sulbactam, and tazobactam against clinically important β-lactamases. Antimicrobial Agents and Chemotherapy 38, 767-72.
37. Knox, J. R. (1995). Extended-spectrum and inhibitor-resistant TEM-type β-lactamases: mutations, specificity, and three-dimensional structure. Antimicrobial Agents and Chemotherapy 39, 2593-601.
38. Matagne, A., Lamotte-Brasseur, J. & Frère, J.-M. (1998). Catalytic properties of class A β-lactamases: efficiency and diversity. Biochemical Joumal 330, 581-98.
39. Fonzé, E., Charlier, P., To'th, Y., Vermeire, M., Raquet, X., Dubus, A. et al. (1995). TEM-1 β-lactamase structure solved by molecular replacement and refined structure of the S235A mutant. Acta Crystallographica, Section D - Biological Crystallography 51, 682-94.
40. Jelsch, C., Mourey, L., Masson, J.-M. & Samama, J.-P. (1993). Crystal structure of Escherichia coli TEM1 β-lactamase at 1.8 Å resolution. Proteins 16, 364-83.
41. Chaïbi, E. B., Farzaneh, S., Péduzzi, J., Barthélémy, M. & Labia, R. (1996). An additional ionic bond suggested by molecular modelling of TEM-2 might induce a slight discrepancy between catalytic properties of TEM-1 and TEM-2 β-lactamases. FEMS Microbiology Letters 143, 121 -5.
42. Blazquez, J., Morosini, M. I., Negri, M. C., Gonzales-Leiza, M. & Baquero, F. (1995). Single amino acid replacements at positions altered in naturally occurring extended-spectrum TEM β-lactamases. Antimicrobial Agents and Chemotherapy 39, 145-9.
43. Herzberg, O. (1991). Refined crystal structure of β-lactamase from Staphylococcus aureus PC1 at 2.0 Å resolution. Journal of Molecular Biology 217, 701-19.
44. Knox, J. R. & Moews, P. C. (1991). β-Lactamase of Bacillus licheniformis 749/C. Refinement at 2 Å resolution and analysis of hydration. Journal of Molecular Biology 220, 435-55.
45. Bonomo, R. A., Dawes, C. G., Knox, J. R. & Shlaes, D. M. (1995). Complementary roles of mutations at positions 69 and 242 in a class A β-lactamase. Biochimica et Biophysica Acta 1247, 113-20.
46. Petit, A., Jullian, E. & Labia, R. (1991). Substitution du tryptophane-165 par une arginine dans la β-lactamase TEM-1. Compte Rendus de l'Académie des Sciences de Paris, Série II 312, 993-7.
47. Farzaneh, S., Chaibi, E. B., Péduzzi, J., Barthélémy, M., Labia, R., Blazquez, J. et al. (1996). Implication of lle-69 and Thr-182 residues in kinetic characteristics of IRT-3 (TEM-32) β-lactamase. Antimicrobial Agents and Chemotherapy 40, 2434-6.
48. Huang, W. & Palzkill, T. (1997). A natural polymorphism in β-lactamase is a global suppressor. Proceedings of the National Academy of Sciences of the USA 94, 8801-6.
49. Péduzzi, J., Reynaud, A., Baron, P., Barthélémy, M. & Labia, R. (1994). Chromosomally encoded cephalosporinase of Proteus vulgaris Ro104 belongs to Ambler's class A. Biochimica et Biophysica Acta 1207, 31-9.
50. Ambler, R. P., Coulson, A. F. W., Frère, J.-M., Ghuysen, J.-M., Joris, B., Forsman, M. et al. (1991). A standard numbering scheme for the class A β-lactamases. Biochemical Journal 276, 269-70.
51. Imtiaz, U., Billings, E., Knox, J. R., Manavathu, E. K., Lerner, S. A. & Mobashery, S. (1993). Inactivation of class A β-lactamases by clavulanic acid: the role of arginine-244 in a proposed nonconcerted sequence of events. Journal of the American Chemical Society 115, 4435-42.
52. Juteau, J.-M., Billings, E., Knox, J. R. & Levesque, R. C. (1992). Site-saturation mutagenesis and three-dimensional modelling of ROβ-1 define a substrate binding role of Ser 130 in class A β-lactamases. Protein Engineering 5, 693-701.
53. Strynadka, N. C. J., Adachi, H., Jensen, S. E., Johns, K., Sielecki, A., Betzel, C. et al. (1992). Molecular structure of the acylenzyme intermediate in β-lactam hydrolysis at 1.7 A resolution. Nature 359, 700-5.
54. Zafaralla, G., Manavathu, E. K., Lerner, S. A. & Mobashery, S. (1992). Elucidation of the role of arginine-244 in the turnover processes of class A β-lactamases. Biochemistry 31, 3847-52.
55. Delaire, M., Labia, R., Samama, J.-P. & Masson, J.-M. (1992). Site-directed mutagenesis at the active site of Escherichia coli TEM-1 β-lactamase. Suicide inhibitor-resistant mutants reveal the role of arginine 244 and methionine 69 in catalysis. Journal of Biological Chemistry 267, 20600-6.
56. Imtiaz, U., Billings, E. M., Knox, J. R. & Mobashery, S. (1994). A structure-based analysis of the inhibition of class A β-lactamases by sulbactam. Biochemistry 33, 5728-38.
57. Imtiaz, U., Manavathu, E. K., Mobashery, S. & Lerner, S. A. (1994). Reversal of clavulanate resistance conferred by a Ser-244 mutant of TEM-1 β-lactamase as a result of a second mutation (Argto-Ser at position 164) that enhances activity against ceftazidime. Antimicrobial Agents and Chemotherapy 38, 1134-9.
58. Taibi, P. & Mobashery, S. (1995). Mechanism of turnover of imipenem by the TEM β-lactamase revisited. Journal of the American Chemical Society 117, 7600-5.
59. 1 pyrroline tautomerization of carbapenem antibiotics by the highly conserved arginine-244 of class A β-lactamases during the course of turnover. Journal of the American Chemical Society 114, 1505-6.
60. Saves, I. (1995). Evolution de la β-lactamase TEM-1. Ph.D. Thesis, University of Toulouse.
61. Saves, I., Burlet-Schiltz, O., Swarén, P., Lefèvre, F., Masson, J.-M., Promé, J. C. et al. (1995). The asparagine to aspartic acid substitution at position 276 of TEM-35 and TEM-36 is involved in the β-lactamase resistance to clavulanic acid. Journal of Biological Chemistry 270, 18240-5.
62. Chen, C. C. H. & Herzberg, O. (1992). Inhibition of β-lactamase by clavulanate. Trapped intermediates in cryocrystallographic studies. Journal of Molecular Biology 224, 1103-13.
63. Brown, R. P. A., Aplin, R. T. & Schofield, C. J. (1996). Inhibition of TEM-2 β-lactamase from Escherichia coli by clavulanic acid: observation of intermediates by electrospray ionisation mass spectrometry. Biochemistry 35, 12421-32.
64. Chaibi, E. B., Farzaneh, S., Morand, A., Péduzzi, J., Barthélémy, M., Sirot, D. et al. (1996). Problems encountered in the characterization of IRT β-lactamases-producing clinical Escherichia coli isolates intermediate-resistant to cephalothin. Journal of Antimicrobial Chemotherapy 37, 190-1.
65. Chardon, H., Farzaneh, S., Labia, R., Jarlier, V., Nicolas, M. H., Paul, G. et al. (1995). Analysis of β-lactamases produced by cephalothin-susceptible Escherichia coli clinical isolates resistant to co-amoxiclav and ticarcillin-clavulanic acid. Journal of Antimicrobial Chemotherapy 36, 267-9.
66. Thomson, C. J. & Amyes, S. G. B. (1995). Back mutations to the TEM-1 β-lactamase from TRC-1 lead to restored sensitivity to clavulanic acid. Journal of Medical Microbiology 42, 429-32.
67. Du Bois, S. K., Marriott, M. S. & Amyes, S. G. B. (1995). TEM- and SHV-derived extended-spectrum β-lactamases: relationship between selection, structure and function. Journal of Antimicrobial Chemotherapy 35, 7-22.
68. Perilli, M., Felici, A., Franceschini, N., De Santis, A., Pagani, L., Luzzaro, F. et al. (1997). Characterization of a new TEM-derived β-lactamase produced in a Serratia marcescens strain. Antimicrobial Agents and Chemotherapy 41, 2374-82.
69. Sirot, D., Recule, C., Chaibi, E. B., Bret, L., Croize, J., Chanal-Claris, C. et al. (1997). A complex mutant of TEM-1 β-lactamase with mutations encountered in both IRT-4 and an extended-spectrum TEM-15 produced by an Escherichia coli clinical isolate. Antimicrobial Agents and Chemotherapy 41, 1322-5.
70. Bonomo, R. A., Currie-McCumber, C. & Shlaes, D. M. (1992). OHIO-1 β-lactamase resistant to mechanism-based inactivators. FEMS Microbiology Letters 71, 79-82.
71. Prinarakis, E. E., Miriagou, V., Tzelepi, E., Gazouli, M. & Tzouvelekis, L. S. (1997). Emergence of an inhibitor-resistant β-lactamase (SHV-10) derived from an SHV-5 variant. Antimicrobial Agents and Chemotherapy 41, 838-40.
72. Bush, K. & Jacob, G. (1997). Nomenclature of TEM β-lactamases. Journal of Antimicrobial Chemotherapy 39, 1-3.
73. Labia, R., Chaibi, E. B., Sirot, D., Chanal-Claris, C., Stapleton, P., Shannon, K. et al. (1998). Inhibitor-resistant TEM β-lactamases: revision of the TEM-41 sequence. Antimicrobial Agents and Chemotherapy 42, 2771.
74. Stapleton, P., Wu, P.-J., King, A., Shannon, K., French, G. & Phillips, I. (1998). Incidence and mechanisms of resistance to the combination of amoxicillin and clavulanic acid in Escherichia coli. [Erratum] Antimicrobial Agents and Chemotherapy 42, 2773.
75. Goussard, S. & Courvalin, P. (1991). Sequence of the genes bla T-1 B and bla T-2. Gene 102, 71-3.
76. Labia, R., Andrillon, J. & Le Goffic, F. (1973). Computerized microacidimetric determination of β-lactamase Michaelis-Menten constants. FEBS Letters 33, 42-4.
77. Caniça, M. M., Barthélémy, M., Gilly, L., Labia, R., Krishnamoorthy, R. & Paul, G. (1997). Properties of IRT-14 (TEM-45), a newly characterized mutant of TEM-type β-lactamases. Antimicrobial Agents and Chemotherapy 41, 374-8.